Why GLP-1 APIs dominate the peptide market

The global peptide active pharmaceutical ingredient (API) market has shifted structurally over the past several years. Demand for glucagon-like peptide-1 (GLP-1) receptor agonists, principally semaglutide and tirzepatide, has grown at a pace that contract manufacturers and commodity suppliers call unprecedented. Why? The answer sits in three places: the biology of these molecules, the manufacturing challenge they present, and the knock-on effects across the peptide supply chain.

What Makes GLP-1 APIs Distinctive

Semaglutide is a 31-amino-acid analogue of the endogenous GLP-1 hormone. A fatty-diacid side chain extends its half-life to roughly one week in humans (published pharmacokinetic estimates put it at about 165–184 hours), which is what allows once-weekly dosing. Tirzepatide is a 39-residue dual agonist targeting both GLP-1 and GIP receptors, first approved by the FDA in May 2022 and marketed as Mounjaro. Both are long-chain peptide APIs, sitting at the more technically demanding end of solid-phase peptide synthesis (SPPS) or hybrid synthesis workflows.

That size has commercial consequences. Longer peptides require more synthesis cycles, more rigorous purification (typically preparative HPLC), and tighter control of impurity profiles under regulatory frameworks such as ICH Q6A. The barrier to entry stays high, and per-gram costs stay elevated relative to shorter research peptides.

Manufacturing Scale-Up Pressures

Mass-market pharmaceutical products need volumes orders of magnitude larger than anything specialty peptides historically demanded. Large-scale manufacturers have responded with documented capacity expansions. Bachem has been building out its Bubendorf, Switzerland site, including a large-volume facility ("Building K") that began commissioning in late 2024. PolyPeptide Group announced in January 2025 an EUR 100-million expansion to roughly double SPPS capacity at its Malmö, Sweden site, and brought new large-scale SPPS capacity online in Braine-l'Alleud, Belgium. Industry reporting consistently describes multi-year order backlogs, capacity constraints, and active qualification of new sites, much of it tied to GLP-1-class demand.

The chemistry is only half of it. Regulatory documentation, quality systems, and supply-chain traceability all expand in proportion. A manufacturer has to hold cGMP compliance across raw material sourcing (protected amino acids, resins, coupling reagents) and finished-API release. Smaller facilities generally can't absorb that coordination load.

Market Dynamics and Spillover Effects

Piling capital and manufacturing attention onto GLP-1 APIs has produced secondary effects throughout the peptide market.

The research-peptide segment covers peptides sold strictly for laboratory or preclinical use, not approved for human consumption, and it sits downstream of all this. Vendors sourcing from contract manufacturers in China or India report that the same facilities producing GLP-1 intermediates also supply research-grade catalogues. A capacity squeeze in one segment can propagate to the other.

Supply Normalization and the Compounding Wind-Down

Things shifted once branded supply caught up with demand. The FDA determined the tirzepatide shortage resolved as of December 19, 2024, and the semaglutide shortage resolved on February 21, 2025, removing both from the agency's drug shortage list. That reclassification triggered phased deadlines for compounding pharmacies (503A) and outsourcing facilities (503B) to wind down compounded GLP-1 production through the spring of 2025. As reported by firms tracking the agency's actions, the move narrowed one large non-branded channel and concentrated legitimate supply back toward approved manufacturers. Downstream availability, in other words, tracks API manufacturing capacity closely.

What the Literature and Industry Describe

Published reviews in peer-reviewed journals describe GLP-1 receptor agonism as a well-characterized mechanism, with a substantial body of clinical trial data accumulated over more than a decade across multiple molecules in the class. Research continues into next-generation formulations: oral, longer-acting, combination agonists. If commercialized, these would place additional demand on peptide synthesis infrastructure. In December 2025 the FDA approved an oral form of semaglutide (a Wegovy pill) for weight management, the first oral GLP-1 cleared for that use. As reported by trade press, that points toward sustained rather than receding peptide-synthesis demand.

On market structure, industry analysts and manufacturer disclosures frame the current period as a capacity-constrained growth phase likely to persist through the latter half of this decade, contingent on how quickly new synthesis capacity comes online. Whether demand normalizes, or whether pipeline molecules keep volumes elevated, remains an open question that market observers describe with significant uncertainty.

For buyers, vendors, and researchers in the peptide space, the practical takeaway is that GLP-1 API dynamics work as a barometer for the broader market. Pricing, lead times, and quality-system expectations set at the pharmaceutical scale tend to migrate into adjacent segments over time.

Sources

• Bachem AG — Peptide API manufacturing
• PolyPeptide Group — Large-scale peptide synthesis
• FDA — Tirzepatide (Mounjaro) approval, Eli Lilly
• Foley & Lardner — FDA removes semaglutide from the drug shortage list (2025)
• Fierce Pharma — Novo Nordisk wins FDA approval for oral Wegovy (2025)
• PMC — Semaglutide pharmacology and pharmacokinetics review
• EMA — Semaglutide product information